Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in locoregionally advanced nasopharyngeal carcinoma
NCT03427827Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2018
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Jul 2018; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03427827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427827.